Cripto-1 Overexpression May Increase Risk of Bladder Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Tumor Biology, researchers have found Cripto-1, an embryonic gene, overexpression may play role in the development of bladder cancer and may have value as a possible prognostic biomarker in patients with bladder cancer.

For the study, researchers sought to investigate the significance of Cripto-1 expression in patients with bladder cancer. To do so, the researchers compared tissue samples of cancerous bladders and noncancerous bladders. They found that Cripto-1 was overexpressed in bladder cancer tissue samples and greatly linked with tumor size (P = 0.003) and tumor grade (P = 0.001).

Furthermore, Cripto-1 overexpression was significantly linked with SRY-related HMG-box gene 2 expression (P = 0.003) and Ki-67 (P = 0.001). SRY-related HMG-box gene 2 regulates gene expression in the stomach and Ki-67 is strongly associated with cell proliferation.

In addition, bladder cancer samples with high Cripto-1 levels were more likely associated with decreased recurrence/metastasis-free survival compared with samples with low Cripto-1 levels (P = 0.011). Statistical analyses demonstrated that Cripto-1 may be a prognostic marker for recurrence/metastasis-free survival (P = 0.036).

Partial, Complete Responses to Bladder-preserving Therapy Yield Similar Outcomes
Cripto-1 gene overexpression may play role in the development of bladder cancer.
The aim of this study is to examine Cripto–1 expression pattern and clinicopathological significance in human bladder cancer patients. The findings suggest that high Cripto–1 expression might be involved in the development of bladder cancer and a potentially effective prognostic marker in bladder cancer patients.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs